Decreased plasma apelin levels in pubertal obese children

Journal of Pediatric Endocrinology and Metabolism

Volumn 23, Issue 10, 2010, Pages 1039-1046

  Tapan, Serkan ^a   Tascilar, Emre ^a   Abaci, Ayhan ^a   Sonmez, Alper ^a   Kilic, Selim ^b   Erbil, M Kemal ^a   Ozcan, Okan ^a  

^a Department of Medical Biochemistry ^*  (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Adiponectin; Apelin; Creactive protein; Insulin resistance; Obesity; Puberty

Indexed keywords

ADIPONECTIN; APELIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL;

ADOLESCENT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; MALE; OBESITY; PREPUBERTY; PRESCHOOL CHILD; PUBERTY; SCHOOL CHILD;

ADOLESCENT; C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; CHOLESTEROL, HDL; FEMALE; HUMANS; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; OBESITY; PUBERTY;

EID: 79951483857     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/jpem.2010.165     Document Type: Article

References (47)

1. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation, Geneva, 3-5 Jun 1997. Geneva: WHO, 1998. (WHO/NUT/98.1.)
2. Kipping RR, Jago R, Lawlor DA. Obesity in children. Part 1: Epidemiology, measurement, risk factors, and screening. BMJ 2008;337:922-7.
3. Ozer BK. Growth reference centiles and secular changes in Turkish children and adolescents. Econ Hum Biol 2007; 5:280-301. (Pubitemid 46876316)
4. Mossberg HO. 40-year follow-up of overweight children. Lancet 1989; 2:491-3.
5. Freedman DS, Dietz WH, Srinivasan SR, Berenson GS. The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. Pediatrics 1999; 103:1175-82. (Pubitemid 29258789)
6. Dabelea D, Hanson RL, Bennett PH, Roumain J, Knowler WC, Pettitt DJ. Increasing prevalence of Type II diabetes in American Indian children. Diabetologia 1998; 41:904-10. (Pubitemid 28365976)
7. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acd Sci 1999; 892:146-54.
8. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998; 251:471-6. (Pubitemid 28505047)
9. Brailoiu GC, Dun SL, Yang J, Ohsawa M, Chang JK, Dun NJ. Apelin-immunoreactivity in the rat hypothalamus and pituitary. Neurosci Lett 2002; 327:193-7. (Pubitemid 34756630)
10. Lee DK, Cheng R, Nguyen T, et al. Characterization of apelin, the ligand for the APJ receptor, J Neurochem 2000;74:34-41. (Pubitemid 30012752)
11. Taheri S, Murphy K, Cohen M, et al. The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats. Biochem Biophys Res Commun 2002; 291:1208-12. (Pubitemid 34694318)
12. Kawamata Y, Habata Y, Fukusumi S, et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta 2001; 1538:162-71. (Pubitemid 32402239)
13. Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005; 146:1764-71. (Pubitemid 40396885)
14. Heinonen MV, Purhonen AK, Miettinen P, et al. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul Pept 2005; 130:7-13. (Pubitemid 40966016)
15. Sörhede Winzell M, Magnusson C, Ahren B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regul Pept 2005; 131:12-7. (Pubitemid 41392985)
16. Bundak R, Furman A, Gunoz H, Darendeliler F, Bas F, Neyzi O. Body mass index references for Turkish children. Acta Paediatr 2006; 95:194-8. (Pubitemid 43189013)
17. Cole TJ, Bellizzi MC, Dietz WH, Flegal KM. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000; 320: 1240-1243. (Pubitemid 30240471)
18. Tümer N, Yalçinkaya F, Ince E, et al. Blood pressure nomograms for children and adolescents in Turkey. Pediatr Nephrol 1999;13:438-43 (Pubitemid 29276742)
19. Marshall WA, Tanner JM. Growth and physiological development during adolescence. Annu Rev Med 1968; 19:283-300.
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-9. (Pubitemid 15018832)
22. Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005; 115:500-3.
23. Dietz WH. Health consequences of obesity in youth: Childhood predictors of adult disease. Pediatrics 1998; 101:518-25. (Pubitemid 28119987)
24. Fagot-Campagna A, Narayan KMV, Imperatore G. Type 2 diabetes in children: [Editorial]. BMJ 2001; 322:377-8.
25. NHANES data on the Prevalence of Overweight Among Children and Adolescents: United States, 2003-2006. CDC National Center for Health Statistics, E.stat(http://www.cdc.gov/nchs/products/pubs/pubd/hestats/ overweight/overwght-child-03.htm).
26. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA 2002; 288:1728-32.
27. McGill HC Jr, McMahan CA, Zieske AW, et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol 2000; 20:1998-2004. (Pubitemid 30644650)
28. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89:2548-56. (Pubitemid 38766330)
29. Emral R. Adiponectin and Other Cytokines: Medical Education. Turkiye Klinikleri J Med Sci 2006;26:409-20. (Pubitemid 44638296)
30. Ebinç H, Ozkurt ZN, Ebinç FA, Yilmaz M, Caglayan O. Adiponectin and insulin resistance in obesityrelated diseases. J Int Med Res 2008; 36:71-9. (Pubitemid 351255972)
31. Yilmaz MI, Sonmez A, Caglar K, et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton) 2007; 12:147-53. (Pubitemid 46426854)
32. Yilmaz MI, Sonmez A, Acikel C, et al. Adiponectin may play a part in the pathogenesis of diabetic retinopathy. Eur J Endocrinol 2004; 151:135-40. (Pubitemid 39117376)
33. Yilmaz MI, Sonmez A, Kilic S, et al. The association of plasma adiponectin levels with hypertensive retinopathy. Eur J Endocrinol 2005;152:233-40 (Pubitemid 40309570)
34. Yenicesu M, Yilmaz MI, Caglar K, et al. Adiponectin level is reduced and inversely correlated with the degree of proteinuria in type 2 diabetic patients. Clin Nephrol 2005; 64:12-9. (Pubitemid 40975060)
35. Lee DK, George SR, O'Dowd B. Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. Trends Pharmacol Sci 2006;27:190-4.
36. Beltowski J. Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity? Med Sci Monit 2006; 12:112-9.
37. Dray C, Knauf C, Daviaud D, et al. Apelin stimulates glucose utilization in normal and obese insulinresistant mice. Cell Metab. 2008; 8:437-45.
38. Castan-Laurell I, Vítkova M, Daviaud D, et al. Effect of hypocaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ. Eur J Endocrinol 2008; 158:905-11.
39. García-Díaz D, Campión J, Milagro FI, Martínez JA. Adiposity dependent apelin gene expression: relationships with oxidative and inflammation markers. Mol Cell Biochem. 2007; 305:87-94. (Pubitemid 47517171)
40. Rayalam S, Della-Fera MA, Krieg PA, Cox CM, Robins A, Baile CA. A putative role for apelin in the etiology of obesity. Biochem Biophys Res Commun 2008; 368:815-9.
41. Erdem G, Dogru T, Tasci I, Sonmez A, Tapan S. Low plasma apelin levels in newly diagnosed Type 2 Diabetes Mellitus. Exp Clin Endocrinol Diabetes 2008; 116:289-92. (Pubitemid 351798738)
42. Tasci I, Dogru T, Naharci I, et al. Plasma apelin is lower in patients with elevated LDL-cholesterol. Exp Clin Endocrinol Diabetes 2007; 115:428-32. (Pubitemid 47234642)
43. Földes G, Horkay F, Szokodi I, et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 2003; 308:480-5. (Pubitemid 36945517)
44. Goetze JP, Rehfeld JF, Carlsen J, et al. Apelin: a new plasma marker of cardiopulmonary disease. Regul Pept 2006; 133: 134-8. (Pubitemid 41820346)
45. Malyszko J, Małyszko JS, Koźminski P, Myśliwiec M. Apelin and cardiac function in hemodialyzed patients: possible relations? Am J Nephrol 2006; 26:121-6. (Pubitemid 43882395)
46. Horlick MB, Rosenbaum M, Nicolson M, Levine LS, Fedun B, Wang J, Pierson RN Jr, Leibel RLEffect of puberty on the relationship between circulating leptin and body composition. J Clin Endocrinol Metab. 2001; 85(7):2509-18.
47. Budak E, Fernández Sánchez M, Bellver J, Cerveró A, Simón C, Pellicer A. Interactions of the hormones leptin, ghrelin, adiponectin, resistin, and PYY3-36 with the reproductive system. Fertil Steril. 2006 Jun; 85(6):1563-81. (Pubitemid 43816423)